The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Expanding the use of targeted therapy for urothelial bladder cancer (UBC): Non-FGFR3 receptor tyrosine kinase (RTK) gene rearrangements (ReAr) and fusions (fus).
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Honoraria - AstraZeneca; Bristol-Myers Squibb; Foundation Medicine; Janssen; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ferring; GlaxoSmithKline; Incyte; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Ipsen; Merck Sharp & Dohme (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche
Other Relationship - Bayer (I)
 
Dean C. Pavlick
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Gennady Bratslavsky
Employment - AptaMatrix
Leadership - Taurus Diagnostics
Stock and Other Ownership Interests - Ilgen; Respiquest
Consulting or Advisory Role - Johnson & Johnson/Janssen; Novartis
 
Joseph M Jacob
Consulting or Advisory Role - Photocure; Verity Pharmaceuticals
 
Oleksandr Kravtsov
No Relationships to Disclose
 
Philippe E. Spiess
Leadership - Global Society of Rare Genitourinary Tumors; NCCN
Honoraria - UptoDate
Other Relationship - NCCN
(OPTIONAL) Uncompensated Relationships - Moffitt Cancer Center
 
Petros Grivas
Consulting or Advisory Role - 4D Pharma; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Dyania Health; EMD Serono; Exelixis; Genentech; GlaxoSmithKline; Guardant Health; Immunomedics; Infinity Pharmaceuticals; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Regeneron; Roche; Seagen
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); EMD Serono (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Kure It Cancer Research (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst)
 
Vamsi Parini
Employment - Foundation Medicine
Stock and Other Ownership Interests - F. Hoffmann LaRoche
 
Brennan Decker
Employment - Foundation Medicine
Stock and Other Ownership Interests - Avidea Technologies; Roche
Consulting or Advisory Role - Foundation Medicine
 
Douglas I. Lin
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche Pharma AG
 
Natalie Danziger
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Mia Alyce Levy
Employment - Foundation Medicine; SeqTech Diagnostics (I)
Leadership - Personalis
Stock and Other Ownership Interests - GenomOncology; Personalis
Honoraria - Roche
Consulting or Advisory Role - GenomOncology, Inc; Personalis; Roche
Research Funding - GenomOncology
Patents, Royalties, Other Intellectual Property - Royalties from GenomOncology for licensing of MyCancerGenome content
Travel, Accommodations, Expenses - Roche
 
Jeffrey S. Ross
Employment - Foundation Medicine
Leadership - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
Consulting or Advisory Role - Celsius Therapeutics; Tango Therapeutics
Research Funding - Foundation Medicine